Molecular Partners AG at RBC Capital Markets Global Healthcare Conference Transcript
We'll continue this afternoon sessions. I'm Alistair Campbell, senior analyst for our European healthcare team. It's my pleasure now to have a session with Molecular Partners, being represented by CEO, Patrick Amstutz, and Seth Lewis.
Questions & Answers
What I'd like to do is just maybe start, Patrick, with just an overview, given the industry has numerous binder technologies that we're all quite familiar with for pharmaceutical applications, whether that be antibodies, antibody fragments, aptamers, [aphamers]. Your program is DARPins, so maybe we can start with an overview of the DARPin technology, its key differentiating factors, and what proof of concept data you've achieved with the platform thus far.
First of all, thanks for the invitation. We're enjoying the conference here, enjoying New York, and having many good
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
